Compare Mesoblast Limited (MESO) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Motorola Solutions Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Motorola Solutions Inc trades at $446.82 (market cap $74.20B). The key difference: Motorola Solutions Inc is far larger — about 41× Mesoblast Limited's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Motorola Solutions Inc for 100 Days on average.
| MESO | MSI | |
|---|---|---|
Market Cap | $1.81B | $74.20B |
Volume | 240,620 | 720,826 |
Sector | Health | Technology |
52-Week High | $20.96 | $491.24 |
52-Week Low | $13.19 | $363.83 |
Typical Hold Time | 14 Days | 100 Days |
Enterprise Value | $1.89B | $83.10B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
MSI trades at $448.48, down 1.72% on the day, amid a bearish technical signal. The company shows strong fundamentals with revenue growth to $11.68 billion in 2025 and a net income margin of 17.44%. Recent news highlights expansion in defense and public safety contracts, including a $139 million Louisiana deal and a $1.5 billion D-Fend acquisition, bolstering its security portfolio. Analyst consensus remains bullish with a $525.86 price target, though cash flow trends show significant investing outflows for growth initiatives.
The outlook for MSI is positive due to robust earnings beats, a record $15.6 billion backlog, and strategic acquisitions enhancing its market position. Risks include high valuation multiples, substantial debt levels, and execution challenges in integrating new acquisitions. Institutional confidence is evident from increased holdings and a $2 billion share repurchase authorization, supporting long-term shareholder value amid near-term cash flow pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
